Pneumonia Clinical Trial
Official title:
Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-centre Randomized Double Blind Controlled Trial in Pakistan
Over a period of years there have been numerous reports from many developing countries
including Pakistan showing a rising treatment failure rate with first line drugs
(amoxicillin and cotrimoxazole) in non-severe pneumonia in children. The reasons for this
rise in treatment failure rates are not entirely clear but one of the reasons is thought to
be increasing antimicrobial resistance of H. influenzae and Strep. pneumoniae to first line
drugs. There is microbiological data which suggests that this resistance can be overcome by
increasing the dose of amoxicillin. The investigators propose to treat non-severe pneumonia
with double dose amoxicillin in an attempt to demonstrate a decrease in treatment failure
rates. This will be a multicentre, double blind randomized controlled trial in children 2-59
months of age with non-severe pneumonia comparing the clinical outcome between the standard
and double dose groups.
It has been felt that the WHO criteria for treatment failure in children with pneumonia are
too stringent and have never been systematically evaluated in the community. The
investigators also propose to modify WHO criteria and field test them in this trial in an
attempt to demonstrate that less stringent treatment failure criteria would have an impact
on the overall treatment failure rates in pneumonia.
Hypothesis:
Therapy outcome with double dose of oral amoxicillin is not different than the standard dose
of amoxicillin, when used for three days for the treatment of non-severe pneumonia in 2-59
months old children.
Status | Completed |
Enrollment | 900 |
Est. completion date | June 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 2 Months to 59 Months |
Eligibility |
Inclusion Criteria: 1. They are aged 2-59 months. 2. Diagnosed with WHO defined non-severe pneumonia (Table 1). Exclusion Criteria: - Children with signs of WHO defined severe or very severe disease. - Known penicillin allergy, with a history of accelerated rash, urticaria, or anaphylactic symptoms. Complicating acute non-pulmonary or chronic illness . - The children living outside the municipal limits of the city who cannot be followed up . - Children who have taken the appropriate doses of WHO-recommended dose of anti microbial drug for 48 hours prior to presentation . - Children who have prior history of wheezing or bronchial asthma and are wheezing now . - Children whose parents or guardians refuse to give consent. - Previously enrolled patients in the present study. - Hospitalization in the past two weeks. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Pakistan | ARI Research Cell, Children Hospital, Pakistan Institute of Medical Sciences | Islamabad | Capital |
Lead Sponsor | Collaborator |
---|---|
ARI Research Cell | World Health Organization |
Pakistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of children with non-severe pneumonia failing treatment with standard and double dose amoxicillin | |||
Secondary | To measure the difference in treatment failure rates by day 5 by using the treatment failure definitions by WHO and the modified study definitions. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Completed |
NCT05815264 -
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
|
Phase 1 | |
Recruiting |
NCT04589936 -
Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care
|
N/A | |
Completed |
NCT02905383 -
The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital
|
N/A | |
Terminated |
NCT03944551 -
Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa
|
N/A | |
Completed |
NCT06210737 -
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years
|
Phase 4 | |
Terminated |
NCT04660084 -
Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Withdrawn |
NCT05702788 -
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04171674 -
Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation.
|
N/A | |
Active, not recruiting |
NCT03140163 -
Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR]
|
N/A | |
Completed |
NCT02638649 -
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
|
||
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Recruiting |
NCT02515565 -
Physiotherapy in Patients Hospitalized Due to Pneumonia.
|
N/A | |
Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
Completed |
NCT01399723 -
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
|
Phase 3 | |
Completed |
NCT01416519 -
Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation
|
N/A | |
Completed |
NCT01446926 -
Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants
|
Phase 1 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Terminated |
NCT02358642 -
Drug to Prevent Pneumonia in the Tube Fed
|
Phase 4 |